CA
NZ
UK
AU
IND
US
Clearmind Medicine has completed a financing transaction that quickly transitioned from debt issuance into equity conversion. The company issued $1.75 million in convertible promissory notes and received $1.58 million in cash proceeds, before the full principal amount was converted into shares by CLA Investors.
Precision BioSciences has taken another operational step forward in the development of PBGENE-HBV, its investigational gene-editing therapy for chronic hepatitis B. The company announced Clinical Trial Application approval to expand the global ELIMINATE-B study into France and Romania.
Arbutus Biopharma has received an important regulatory milestone after the U.S. Food and Drug Administration granted Fast Track designation to imdusiran for chronic hepatitis B.
Allogene Therapeutics has announced a substantial equity financing aimed at reinforcing its balance sheet and supporting continued advancement of its allogeneic CAR-T cell therapy pipeline.
Medicus Pharma is set to present new Phase 1 clinical data at AACE 2026 for Teverelix, its long-acting GnRH antagonist candidate. The update is notable because it addresses several critical considerations for hormone-modulating therapies: efficacy consistency, reversibility, dosing convenience, bone health, and tolerability.
Strategic Partnership in Ophthalmology Devices and Group Purchasing Organizations (GPOs)Iridex Corporation, a provider of laser-based medical systems for ophthalmology, has entered into a partnership with EyeProGPO, a U.S.-focused group purchasing organization serving more than 1,800 ophthalmology practices, ambulatory surgery centers, and hospitals. The agreement …
AtaiBeckley Inc. has reported Phase 2a clinical data for BPL-003, an intranasal psychedelic-based therapy targeting treatment-resistant depression (TRD), highlighting both rapid onset and sustained efficacy. The findings arrive as investor and industry attention toward next-generation mental health treatments continues to expand, particularly in segments …
FDA Orphan Drug Designation Expands Scope in Pediatric Brain Cancer TreatmentPlus Therapeutics has secured U.S. FDA Orphan Drug Designation for REYOBIQ, its investigational radiotherapeutic targeting pediatric malignant gliomas. Notably, the designation extends beyond the company’s initial request to include pediatric ependymoma, broadening the potential …
iBio, Inc. has taken a notable step in its development trajectory with regulatory clearance in Australia to initiate a first-in-human Phase 1 trial for IBIO-600. The Clinical Trial Notification acknowledgement from the Therapeutic Goods Administration, alongside ethics approval, enables the company to begin dosing …
UroGen Pharma Expands Clinical Engagement in LG-UTUC Treatment LandscapeUroGen Pharma Ltd. has introduced its “LG-UTUC Luminaries” initiative, a clinician- and institution-focused program aimed at advancing care standards for low-grade upper tract urothelial cancer (LG-UTUC). The initiative underscores the company’s broader strategy of embedding itself …
Please wait processing your request...